ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on July 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 16,800 shares of its common stock to a new employee under the ImmunoGen, Inc.
August 3, 2020
· 2 min read